Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price

Adalimumab, Infliximab And Etanercept Biosimilars Market 2022 – By Product (Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab), By Application (Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2031

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

Starting Price : $5000.00 $3500.00 | Pages : 252 | Published : October 2022 | | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Adalimumab, Infliximab And Etanercept Biosimilars Market Definition

The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules namely Humira, Remicade and Enbrel, respectively.

Book your 30 minutes free consultation with our research experts

Contact Us

Adalimumab, Infliximab And Etanercept Biosimilars Market Size

The global adalimumab, infliximab and etanercept biosimilars market size reached a value of nearly $2,757.45 million in 2021, having grown at a compound annual growth rate (CAGR) of 93.90% since 2016. The global adalimumab, infliximab and etanercept biosimilars market size is expected to grow from $2,757.45 million in 2021 to $5,591.82 million in 2026 at a rate of 15.20%. The global adalimumab, infliximab and etanercept biosimilars market size is then expected to grow at a CAGR of 9.96% from 2026 and reach $8,991.32 million in 2031.    

Growth in the historic period resulted from increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives and rising healthcare costs. The market was restrained by the companies gaining market share without a simple price war, low healthcare access and a lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, a rise in healthcare expenditure, aging population and an increase in healthcare access will drive dalimumab, infliximab and etanercept biosimilars market growth. Factors that could hinder the growth of the adalimumab, infliximab and etanercept biosimilars market in the future include insufficient and outdated health system infrastructure.

Adalimumab, Infliximab And Etanercept Biosimilars Market Drivers

The key drivers of the adalimumab, infliximab and etanercept biosimilars market include:

Rise In Healthcare Expenditure

  • Increasing healthcare expenditure is also rising in healthcare costs that is predicted to increase the demand for the adalimumab, infliximab and etanercept biosimilars market if the cost of biosimilar is reduced.

  • According to the National Health Expenditure Projections 2018-2027, by 2027 the national healthcare expenditure in the USA is expected to reach nearly $6.0 trillion, which is growing at an average rate of 5.5% annually from 2018 to 2027. Annually, Prescription drug spending is projected to grow by 6.1% during 2020-2027. Consequently, the rise in healthcare spending is to increase the market for adalimumab, infliximab and etanercept biosimilars in the near future.

    • Adalimumab, Infliximab And Etanercept Biosimilars Market Restraints

    The key restraints on the adalimumab, infliximab and etanercept biosimilars market include:

    Insufficient And Outdated Health System

  • Insufficient and outdated health system infrastructure (facilities, technology, clinicians) remains, for many, a major hurdle to achieving health equity.
    •  

  • Fewer than 50% of Africans have access to modern health facilities. Further, around 61% of births were attended by skilled health staff in 2018, far fewer than the 80% global average. And although more people in India’s smaller towns and rural areas now have money for health care through the new PMSBY insurance scheme, they have limited options to use it because clinician and product supply is limited, and government health facilities are few and far between.
    •  

  • As of 2019, 9.6% of the 24,855 primary health centers (PHCs) in India had no doctor, 38.4% had no laboratory technician, and 23.9% had no pharmacist. There are also severe gaps in skilled professionals: For rural community health centers in 2019, only 15% of the surgical posts, 13% of the physician posts, 25% of the obstetrics and gynecology posts, and 20% of the pediatrician posts were filled.

    • Adalimumab, Infliximab And Etanercept Biosimilars Market Trends

    Major trends influencing the adalimumab, infliximab and etanercept biosimilars market include:

    Robust Competition in the Marketplace

  • Biosimilars are being launched in new territories and geographies. For example, in February 2021, Viatris Inc., American global healthcare company, launched Hulio (Adalimumab Biosimilar) in Canada. This launch has increased patient access resulting in better health, by providing Canadian patients with chronic inflammatory disorders with an additional treatment option.

  • Also, in February 2021 Sandoz Canada, launched Hyrimoz (adalimumab biosimilar injection). Sandoz is maximizing the value of Hyrimoz by maximizing approved indications to nine of the twelve serious debilitating or life-threatening conditions in adults and children treated by the reference medicine.

  • The demand for agents to treat autoimmune disease such as Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis has been increasing. Due to the high cost of originator biologicals the EMA and the FDA have each granted license to a number of TNFa biosimilars to increase competition and drive costs down.

  • For example, by the end of 2023, seven or more Humira biosimilar competitors are expected to launch in the US. Humira has undergone numerous changes over the period such as, new concentrations, citrate-free variations, latex-free delivery methods, and smaller needle gauges as part of AbbVie’s strategy to protect their franchise. The biosimilar companies will have to compete aggressively in the market place to capture market share from Humira. With an average monthly treatment cost of $6,000 for Humira, much of this competition will be based on price.

    • Growing Mergers And Acquisitions

  • The focus areas for many companies in the adalimumab, infliximab and etanercept biosimilars market have shifted to increasing mergers and acquisitions to acquire more production capabilities. Large prime manufacturers are forming joint ventures or buying small or midsized companies to acquire new capabilities or gain access to new markets.

  • For example, in February 2022, Biocon Biologics, India based biopharmaceutical company (a subsidiary of Biocon Ltd.), acquired Viatris’ Biosimilars for a deal value of $3.3 billion. Viatris is a US-based pharmaceutical company.

  • Also, in November 2019, Biogen Inc, a US-based multinational biotechnology company based in Cambridge, Massachusetts, acquired Samsung Bioepis Co., Ltd. to get the exclusive powers to market two new ophthalmology biosimilars, SB11 referencing Lucentis 1 and SB15 referencing Eylea 2, in major markets globally, including the U.S., Canada, Europe, Japan, and Australia. Samsung Bioepis is a biopharmaceutical company. It produces biosimilars medicines and other related products.

    • Opportunities And Recommendations In The Adalimumab, Infliximab And Etanercept Biosimilars Market

    Opportunities –The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by product will arise in the adalimumab biosimilars market segment, which will gain $1,165.5 million of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by application will arise in the other applications market segment, which will gain $ 601.4 of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel will arise in the hospital pharmacies market segment, which will gain $1,939.2 of global annual sales by 2026. The global adalimumab, infliximab and etanercept biosimilars market size will gain the most in the USA at $738.0 million.

    Recommendations –To take advantage of the opportunities, The Business Research Company recommends the adalimumab, infliximab and etanercept biosimilars companies to focus on new product launches, expand in emerging markets, increase focus on mergers and acquisitions, offer competitive pricing, continue to participate in events and conferences and focus on fast-growing applications.

    Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation

    The adalimumab, infliximab and etanercept biosimilars market is segmented by product, by application, and by distribution channel.
    By Product –
    The adalimumab, infliximab and etanercept biosimilars market is segmented by product into
      • a) Adalimumab Biosimilars
      • b) Infliximab Biosimilars
      • c) Cipleumab
    The adalimumab, infliximab and etanercept biosimilars market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by product, accounting for 39.33% of the total in 2021. Going forward, the Cipleumab segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by product, at a CAGR of 17.18% during 2021-2026.
    By Application–
    The adalimumab, infliximab and etanercept biosimilars market is segmented by application into
      • a) Crohn’s Disease
      • b) Psoriatic Arthritis
      • c) Rheumatoid Arthritis
      • d) Ulcerative Colitis
      • e) Ankylosing Spondylitis
      • f) Plaque Psoriasis
      • g) Other Applications
    The other applications market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by application, accounting for 20.1% of the total in 2021. Going forward, the other applications segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by application, at a CAGR of 15.8% during 2021-2026.
    By Distribution Channel –
    The adalimumab, infliximab and etanercept biosimilars market is segmented by distribution channel into
      • a) Hospital Pharmacies
      • b) Retail Pharmacies
      • c) Online Pharmacies
    The hospital pharmacies market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, accounting for 87.7% of the total in 2021. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, at a CAGR of 32.2% during 2021-2026.
    By Geography- The adalimumab, infliximab and etanercept biosimilars market is segmented by geography into
      • o Asia Pacific
        • •  China
        • •  Japan
        • •  India
        • •  Australia
        • •  Indonesia
        • •  South Korea
        • o North America
        • • USA
        o South America
        • • Brazil 
        o Western Europe
        • • UK 
        • • Germany 
        • • France 
        o Eastern Europe
        • • Russia 
        o Middle East
        o Africa
    Western Europe was the largest region in the global adalimumab, infliximab and etanercept biosimilars market, accounting for 86.3% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the global adalimumab, infliximab and etanercept biosimilars market will be Africa, and, Eastern Europe where growth will be at CAGRs of 110.4% and 56.5% respectively. These will be followed by Middle East, and, South America where the markets are expected to grow at CAGRs of 52.9% and 50.3% respectively.

    Adalimumab, Infliximab And Etanercept Biosimilars Market Competitive Landscape

    Major Competitors are:

  • Biogen
  • Novartis (Sandoz)
  • Pfizer
  • Amgen
  • Celltrion

    • Other Competitors Include:

  • Samsung Bioepis (Samsung Biologics)
  • Hetero Drugs Limited
  • Fresenius Kabi AG
  • Boehringer Ingelheim
  • Biocon
  • Zydus Lifesciences Limited
  • Reliance Life Sciences
  • Torrent Pharmaceuticals Ltd
  • Sun Pharmaceutical Industries Ltd
  • Cipla Limited
  • Zhejiang Hisun Pharmaceutical Co. Ltd
  • Bio- Thera Solutions, Ltd
  • Innovent Biologics (Suzhou) Co. Ltd
  • Janssen Biologics BV
  • Shanghai CP Guojian Pharmaceutical Co. Ltd
  • Sansheng Guojian
  • Shanghai Junshi Biosciences Co. Ltd
  • Mabwell Bioscience Co. Ltd
  • LG Chem
  • Nippon Kayaku
  • Mochida Pharmaceutical Co. Ltd
  • mAbxience
  • Allergan
  • Microgen
  • Geropharm
  • Valenta
  • NovaMedica Veropharm
  • Biocad
  • Roche
  • Bristol-Myers Squibb
  • Celon Pharma
  • SynBio
  • Celgene Corporation
  • AstraZeneca
  • Merck & Co
  • Gilead Sciences
  • Regeneron Pharmaceuticals
  • Rani Therapeutics
  • Eli Lilly and Company
  • Emisphere Technologies Inc
  • Enteris BioPharma
  • Allena Pharmaceuticals
  • Abbvie
  • Johnson & Johnson
  • Ache
  • Eurofarma
  • Sanofi
  • Teva Pharmaceuticals
  • Oramed Pharmaceuticals
  • Entera Bio
  • Julphar
  • Hikma Pharmaceuticals
  • Mylan
  • BIOPHARMA-MEA
  • NeoTX
  • AID Genomics Limited
  • Altis Biologics
  • Cipla Medpro South Africa
  • Sanofi Genzyme
  • Next Biosciences
  • Viome
  • Inqaba Biotechnical Industries (Pty) Ltd

      • Table Of Contents

      1. Adalimumab, Infliximab And Etanercept Biosimilars Market Executive Summary

      2. Table of Contents

      3. List of Figures

      4. List of Tables

      5. Report Structure

      6. Introduction and Market Characteristics

      6.1. General Market Definition

      6.2. Summary

      6.3. Adalimumab, Infliximab And Etanercept Biosimilars Market Definition and Segmentations

      6.4. Market Segmentation By Product

      6.4.1. Adalimumab Biosimilars

      6.4.2. Infliximab Biosimilars

      6.4.3. Etanercept Biosimilars

      6.5. Market Segmentation By Application

      6.5.1. Crohn’s Disease

      6.5.2. Psoriatic Arthritis

      6.5.3. Rheumatoid Arthritis

      6.5.4. Ulcerative Colitis

      6.5.5. Ankylosing Spondylitis

      6.5.6. Plaque Psoriasis

      6.5.7. Other Applications

      6.6. Market Segmentation By Distribution Channel

      6.6.1. Hospital Pharmacies

      6.6.2. Retail Pharmacies

      6.6.3. Online Pharmacies

      7. Major Market Trends

      7.1. Robust Competition in the Marketplace

      7.2. Growing Mergers And Acquisitions

      7.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development

      7.4. Large Number Of Strategic Partnerships

      7.5. Increasing Investments In Biosimilars Market

      8. Global Market Size And Growth

      8.1. Market Size

      8.2. Historic Market Growth, 2016 – 2021, Value ($ Million)

      8.2.1. Market Drivers 2016 – 2021

      8.2.2. Market Restraints 2016 – 2021

      8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      8.3.1. Market Drivers 2021 – 2026

      8.3.2. Market Restraints 2021 – 2026

      9. Adalimumab, Infliximab and Etanercept Biosimilars Market, Regional Analysis

      9.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      9.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      10. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

      10.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      10.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      10.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distributional Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11. Asia-Pacific Market

      11.1. Summary

      11.2. Asia Pacific Market Overview

      11.2.1. Region Information

      11.2.2. Market Information

      11.2.3. Background Information

      11.2.4. Government Initiatives

      11.2.5. Regulations

      11.2.6. Regulatory Bodies

      11.2.7. Major Associations

      11.2.8. Taxes Levied

      11.2.9. Corporate Tax Structure

      11.2.10. Investments

      11.2.11. Major Companies

      11.3. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.4. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.5. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.6. Asia Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

      11.7. China Market

      11.8. Summary

      11.9. China Market Overview

      11.9.1. Country Information

      11.9.2. Market Information

      11.9.3. Background Information

      11.9.4. Government Initiatives

      11.9.5. Regulations

      11.9.6. Regulatory Bodies

      11.9.7. Major Associations

      11.9.8. Taxes Levied

      11.9.9. Corporate Tax Structure

      11.9.10. Investments

      11.9.11. Major Companies

      11.10. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.11. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.12. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.13. India Market

      11.14. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.15. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.16. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.17. Japan Market

      11.18. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.19. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.20. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.21. Australia Market

      11.22. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.23. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.24. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.25. Indonesia Market

      11.26. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.27. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.28. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.29. South Korea Market

      11.30. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.31. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.32. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12. Western Europe Market

      12.1. Summary

      12.2. Western Europe Market Overview

      12.2.1. Region Information

      12.2.2. Market Information

      12.2.3. Background Information

      12.2.4. Government Initiatives

      12.2.5. Regulations

      12.2.6. Regulatory bodies

      12.2.7. Major Associations

      12.2.8. Taxes Levied

      12.2.9. Corporate Tax Structure

      12.2.10. Investments

      12.2.11. Major Companies

      12.3. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.4. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.5. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.6. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

      12.7. UK Market

      12.8. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.9. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.10. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.11. Germany Market

      12.12. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.13. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.14. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.15. France Market

      12.16. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.17. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.18. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13. Eastern Europe Market

      13.1. Summary

      13.2. Eastern Europe Market Overview

      13.2.1. Region Information

      13.2.2. Market Information

      13.2.3. Background Information

      13.2.4. Government Initiatives

      13.2.5. Regulations

      13.2.6. Regulatory Bodies

      13.2.7. Major Associations

      13.2.8. Taxes Levied

      13.2.9. Corporate Tax Structure

      13.2.10. Investments

      13.2.11. Major Companies

      13.3. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.4. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.5. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.6. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

      13.7. Russia Market

      13.8. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.9. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.10. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14. North America Market

      14.1. Summary

      14.2. North America Market Overview

      14.2.1. Region Information

      14.2.2. Market Information

      14.2.3. Background Information

      14.2.4. Government Initiatives

      14.2.5. Regulations

      14.2.6. Regulatory Bodies

      14.2.7. Major Associations

      14.2.8. Taxes Levied

      14.2.9. Corporate tax structure

      14.2.10. Investments

      14.2.11. Major Companies

      14.3. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.4. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.5. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.6. North America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

      14.7. USA Market

      14.8. Summary

      14.9. USA Market Overview

      14.9.1. Country Information

      14.9.2. Market Information

      14.9.3. Background Information

      14.9.4. Government Initiatives

      14.9.5. Regulations

      14.9.6. Regulatory Bodies

      14.9.7. Major Associations

      14.9.8. Taxes Levied

      14.9.9. Corporate Tax Structure

      14.9.10. Investments

      14.9.11. Major Companies

      14.10. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.11. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.12. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15. South America Market

      15.1. Summary

      15.2. South America Market Overview

      15.2.1. Region Information

      15.2.2. Market Information

      15.2.3. Background Information

      15.2.4. Government Initiatives

      15.2.5. Regulations

      15.2.6. Regulatory Bodies

      15.2.7. Major Associations

      15.2.8. Taxes Levied

      15.2.9. Corporate Tax Structure

      15.2.10. Investments

      15.2.11. Major Companies

      15.3. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      15.4. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      15.5. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15.6. South America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

      15.7. Brazil Market

      15.8. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      15.9. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      15.10. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      16. Middle East Market

      16.1. Summary

      16.2. Middle East Market Overview

      16.2.1. Region Information

      16.2.2. Market Information

      16.2.3. Background Information

      16.2.4. Government Initiatives

      16.2.5. Regulations

      16.2.6. Regulatory Bodies

      16.2.7. Major Associations

      16.2.8. Taxes Levied

      16.2.9. Corporate Tax Structure

      16.2.10. Investments

      16.2.11. Major Companies

      16.3. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      16.4. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      16.5. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      17. Africa Market

      17.1. Summary

      17.2. Africa Market Overview

      17.2.1. Region Information

      17.2.2. Market Information

      17.2.3. Background Information

      17.2.4. Government Initiatives

      17.2.5. Regulations

      17.2.6. Regulatory Bodies

      17.2.7. Major Associations

      17.2.8. Taxes Levied

      17.2.9. Corporate Tax Structure

      17.2.10. Investments

      17.2.11. Major Companies

      17.3. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      17.4. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      17.5. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      18. Competitive Landscape And Company Profiles

      19. Company Profiles

      19.1. Biogen

      19.1.1. Company Overview

      19.1.2. Products And Services.

      19.1.3. Business Strategy

      19.1.4. Financial Overview

      19.2. Novartis AG (Sandoz)

      19.2.1. Company Overview

      19.2.2. Products And Services.

      19.2.3. Business Strategy

      19.2.4. Financial Overview

      19.3. Pfizer Inc.

      19.3.1. Company Overview

      19.3.2. Products And Services

      19.3.3. Business Strategy

      19.3.4. Financial Overview

      19.4. Amgen Inc

      19.4.1. Company Overview

      19.4.2. Products And Services.

      19.4.3. Business Strategy

      19.4.4. Financial Overview

      19.5. Celltrion

      19.5.1. Company Overview

      19.5.2. Products And Services

      19.5.3. Business Strategy

      19.5.4. Financial Overview

      20. Pipeline Analysis

      21. Key Mergers And Acquisitions In The Market

      21.1. Fresenius Kabi Acquired mAbxience

      21.2. Biocon Biologics to Acquire Viatris Biosimilars Business

      21.3. Celltrion Acquired Assets Of Takeda Pharmaceuticals

      21.4. Amgen Acquired Japanese JV with Astellas

      21.5. True North Acquired Stake In Biocon Biologics Ltd.

      21.6. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India

      21.7. Ligand Pharmaceuticals Acquired Pfenex

      21.8. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.

      21.9. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital

      21.10. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech

      21.11. Biocon Merged With Sandoz

      22. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Opportunities And Strategies

      22.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 – Countries Offering Most New Opportunities

      22.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 – Segments Offering Most New Opportunities

      22.3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market In 2026 – Growth Strategies

      22.3.1. Market Trend Based Strategies

      22.3.2. Competitor Strategies

      23. Adalimumab, Infliximab and Etanercept Biosimilars Market, Conclusions And Recommendations

      23.1. Conclusions

      23.2. Recommendations

      23.2.1. Product

      23.2.2. Place

      23.2.3. Price

      23.2.4. Promotion

      23.2.5. People

      24. Appendix

      24.1. Market Data Sources

      24.2. Research Methodology

      24.3. Currencies

      24.4. The Business Research Company

      24.5. Copyright and Disclaimer

    List Of Tables

      Table 1: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 2: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 3: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 4: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 5: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 6: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 7: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 8: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 9: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 10: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 11: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 12: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 13: Asia-Pacific Population By Age Group, By Country, 2016-2026, Thousands
    • Table 14: Asia-Pacific GDP Per Capita, By Country, 2016-2021, $
    • Table 15: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 16:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 17: Asia-Pacific, Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 18: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 19: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 20: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 21: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 22: China Population By Age Group, 2016-2026, Thousands
    • Table 23: China GDP Per Capita, 2016-2021, $
    • Table 24:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 25: China Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 26: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 27: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 28: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 29: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 30: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 31: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 32: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 33: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 34: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 35: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 36: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 37: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 38: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 39: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 40: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 41: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 42: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 43: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 44: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 45: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 46: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 47: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 48: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 49: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 50: Western Europe Population By Age Group, By Country, 2016-2026, Thousands
    • Table 51: Western Europe GDP Per Capita, By Country, 2016-2021, $
    • Table 52:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 53:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 54: Western Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 55: Western Smart Europe Washing Machines Market, Historic, 2016 – 2021, $ Million
    • Table 56: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 57: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 58: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 59: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 60: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 61: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 62: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 63: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 64: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 65: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 66: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 67: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 68: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 69: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 70: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 71: Eastern Europe Population By Age Group, By Country, 2016-2026, Thousands
    • Table 72: Eastern Europe GDP Per Capita, By Country, 2016-2021, $
    • Table 73:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 74:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 75: Eastern Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 76: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 77: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 78: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 79: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 80: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 81: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 82: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 83: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 84: North America Population By Age Group, By Country, 2016-2026, Thousands
    • Table 85: North America GDP Per Capita, By Country, 2016-2021, $
    • Table 86:  North America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 87:  North America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 88: North America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 89: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 90: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 91: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 92: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 93: USA Population By Age Group, 2016-2026, Thousands
    • Table 94: USA GDP Per Capita, 2016-2021, $
    • Table 95:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 96: USA Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 97: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 98: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 99: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 100: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 101: South America Population By Age Group, By Country, 2016-2026, Thousands
    • Table 102: South America GDP Per Capita, By Country, 2016-2021, $
    • Table 103:  South America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 104:  South America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 105: South America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 106: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 107: South America Washing Machines Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 108: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 109: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 110: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 111: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 112: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 113: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 114: Middle East Population By Age Group, By Country, 2016-2026, Thousands
    • Table 115: Middle East GDP Per Capita, By Country, 2016-2021, $
    • Table 116:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 117:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 118: Middle East Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 119: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 120: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 121: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 122: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 123: Africa Population By Age Group, By Country, 2016-2026, Thousands
    • Table 124: Africa GDP Per Capita, By Country, 2016-2021, $
    • Table 125:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 126:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 127: Africa Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 128: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 129: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 130: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 131: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 132: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
    • Table 133: Biogen – Financial Performance, 2017– 2021, $ Billion
    • Table 134 Novartis – Financial Performance, 2017– 2021, $ Billion
    • Table 135: Pfizer – Financial Performance, 2017– 2021, $ Billion
    • Table 136 Amgen – Financial Performance, 2017– 2021, $ Billion
    • Table 137: Celltrion – Financial Performance, 2017– 2021, $ Billion
    • Table 138: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), 2021 – 2026, By Country
    • Table 139: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Product, 2021 – 2026
    • Table 140: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2021 – 2026
    • Table 141: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2021 – 2026
    • Table 142: Adalimumab, Infliximab and Etanercept Biosimilars Market Data Sources

    List Of Figures

      Figure 1: Geographic Regions Covered
    • Figure 2: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Product
    • Figure 3: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Application
    • Figure 4: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Distribution Channel
    • Figure 5: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 6: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 7: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 8: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 9: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 10: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 11: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 12: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 13: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 14: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 15: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 16: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 17: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 18: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 19: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 20: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 21: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 22: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 23: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 24: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 25: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 26: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 27: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 28: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 29: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 30: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 31: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 32: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 33: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 34: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 35: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 36: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 37: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 38: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 39: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 40: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 41: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 42: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 43: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 44: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 45: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 46: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 47: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 48: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 49: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 50: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 51: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 52: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 53: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 54: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 55: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 56: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 57: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 58: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 59: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 60: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 61: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 62: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 63: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 64: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 65: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 66: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 67: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 68: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 69: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
    • Figure 70: Biogen – Financial Performance, $ Billion
    • Figure 71: Novartis – Financial Performance, 2017– 2021, $ Billion
    • Figure 72: Pfizer – Financial Performance, 2017– 2021, $ Billion
    • Figure 73: Amgen – Financial Performance, 2017– 2021, $ Billion
    • Figure 74: Celltrion – Financial Performance, 2017– 2021, $ Billion

    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

    Read More

    Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

    Read More

    Global Gene Therapy Market 2022 – Market Opportunities And Strategies

    Read More

    The Microbiome Market Share, Market Size, And Growth Rate 2022

    Read More

    Latest Digestive Health Supplements Market Growth Study 2022-2026 By The Business Research Company

    Read More

    The Business Research Company offers the pancreatic cancer drugs market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the fertility drugs market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the antivirals market research report 2022 with industry size, share, segments and market growth

    Read More

    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Enzymes Global Market Report 2024 – By Product Type (Asparaginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products), By Application (Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications), By End User (Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Protein Inhibitors Global Market Report 2024 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Oral Biologics & Biosimilar Drugs Global Market Report 2024 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Digestive Enzymes Global Market Report 2024 – By Enzyme Type (Carbohydrates, Protease, Lipase, Other Enzyme Types), By Origin (Animal, Fungi, Microbial, Plant), By Application (Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications), By Distribution Channel (Retail Stores, Online Stores) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Frequently Asked Questions

    What is the definition of the adalimumab, infliximab and etanercept biosimilars market?

    Adalimumab, infliximab, and etanercept biosimilars refer to a novel class of medications that work to inhibit the effects of the inflammatory mediator tumour necrosis factor-alpha (TNF-alpha). A chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-alpha) is known as an infliximab biosimilar. Immune system disorders are treated with it. For further insights on the adalimumab, infliximab and etanercept biosimilars market, request a sample here

    How will the adalimumab, infliximab and etanercept biosimilars market drivers and restraints affect the adalimumab, infliximab and etanercept biosimilars market dynamics? What forces will shape the adalimumab, infliximab and etanercept biosimilars industr

    The adalimumab, infliximab and etanercept biosimilars market growth is aided by the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade. However, some adalimumab, infliximab and etanercept biosimilars market restraints include patent extension of Humira (adalimumab). For further insights on the adalimumab, infliximab and etanercept biosimilars market, request a sample here

    What is the forecast market size or the forecast market value of the adalimumab, infliximab and etanercept biosimilars market?

    The adalimumab, infliximab and etanercept biosimilars market is expected to reach $25.73 billion in 2027 at a rate of 42.5%. For further insights on the adalimumab, infliximab and etanercept biosimilars market, request a sample here

    How is the adalimumab, infliximab and etanercept biosimilars market segmented?

    The global adalimumab, infliximab and etanercept biosimilars market is segmented as
    1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)
    2) By Application: Crohn’S Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
    3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
    For further insights on the adalimumab, infliximab and etanercept biosimilars market,     request a sample here

    Which region has the largest share of the adalimumab, infliximab and etanercept biosimilars market? What are the largest region's market size and growth rate?

    North America was the largest region in the adalimumab, infliximab and etanercept biosimilars market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

    Who are the major players in the adalimumab, infliximab and etanercept biosimilars market?

    Key competitors in the adalimumab, infliximab and etanercept biosimilars market are, Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, Abbvie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd, Glenmark pharmaceuticals, Cipla Ltd, Emcure Pharmaceuticals Ltd. For further insights on the adalimumab, infliximab and etanercept biosimilars market, request a sample here.

    What are the key trends in the adalimumab, infliximab and etanercept biosimilars market?

    Major trends influencing the adalimumab, infliximab and etanercept biosimilars market include replacement of brand-name versions of biosimilar drugs have high costs with biosimilar versions upon their patent’s expiry. The cost of branded biological drugs has almost doubled in recent years. For further insights on the adalimumab, infliximab and etanercept biosimilars market, request a sample here.

    What are the major opportunities in the adalimumab, infliximab and etanercept biosimilars market? What are the strategies for the adalimumab, infliximab and etanercept biosimilars market?

    For detailed insights on the major opportunities and strategies in the adalimumab, infliximab and etanercept biosimilars market, request a sample here.

    How does the adalimumab, infliximab and etanercept biosimilars market relate to the overall economy and other similar markets?

    For detailed insights on adalimumab, infliximab and etanercept biosimilars market's relation to the overall economy and other similar markets, request a sample here.

    What are the latest mergers and acquisitions in the adalimumab, infliximab and etanercept biosimilars industry?

    For detailed insights on the mergers and acquisitions in the adalimumab, infliximab and etanercept biosimilars industry, request a sample here.

    What are the key dynamics influencing the adalimumab, infliximab and etanercept biosimilars market growth? SWOT analysis of the adalimumab, infliximab and etanercept biosimilars market.

    For detailed insights on the key dynamics influencing the adalimumab, infliximab and etanercept biosimilars market growth and SWOT analysis of the adalimumab, infliximab and etanercept biosimilars industry, request a sample here.